Manipal Health vs Max Healthcare: Which Hospital Stock is Better?

Business Overview

# Manipal Health Enterprises

Manipal Health Enterprises is India's largest private hospital network by bed capacity. As of March 2026, it operated 49 hospitals with 13,037 licensed beds and 21 clinics across 14 states and union territories, giving it the widest geographic footprint of any private chain in the country.

The company is part of the Manipal Group, founded by Dr T.M.A. Pai. It has decades of recognition in Indian healthcare and education. It's backed by Temasek, Singapore's sovereign investor.

Manipal focuses on six high-acuity specialities it calls CONGO-R: cardiac sciences, oncology, neurosciences, gastro sciences, orthopedics, and renal sciences. These contributed 64.3% of gross inpatient revenue in FY26, up from 61.6% in FY24.

High-acuity work matters because it generates more revenue per patient, though it also demands specialised equipment and senior clinicians. Its clinical infrastructure includes 58 cath labs, 44 MRI scanners, 19 LINACs, and robotic surgical systems.

As of March 2026, it employed 11,064 doctors, 11,048 nurses, and 6,362 paramedics, and treated 7.63 m patients during FY26.

Much of its recent scale has come through acquisition. Between March 2024 and March 2026, the network grew from 33 hospitals and 9,520 beds to 49 hospitals and 13,037 beds, absorbing AMRI, Medica Synergie and the Sahyadri Group along the way.

It's also the only private hospital chain with a simultaneous presence in three metro markets: Bengaluru, Kolkata, and Delhi NCR.

# Max Healthcare Institute

Max Healthcare is India's largest hospital chain by market capitalisation and the second largest by revenue and EBITDA.

Its model is different from Manipal's. Rather than spreading wide, Max concentrates on dense, high-income urban clusters, principally Delhi NCR, along with Mumbai, Lucknow, Dehradun, and Mohali. Fewer hospitals, fewer beds, but positioned in markets where patients can and do pay more.

That focus shows up in its revenue quality. Max consistently records the highest average revenue per occupied bed among listed Indian hospital chains, a direct reflection of case mix and pricing power.

Beyond hospitals, the company runs Max Lab, a non-captive pathology business present in over 60 cities offering more than 2,700 tests, and Max@Home, which delivers physiotherapy, rehabilitation, critical care assistance, and medicine delivery to patients' homes.

Oncology is its largest single revenue contributor at roughly 24%, and management expects that share to exceed 30% over the medium term as radiation oncology facilities at Lucknow and Dwarka come on stream.

International patients contribute around 9% of hospital revenue, supported by direct-to-fly marketing offices in overseas source markets.

Manipal has more than twice the beds and operates across more than twice as many states, yet Max has a market capitalisation roughly 37% higher.

The market is paying more for a smaller network, which tells you it values something other than size.

# Revenue

Manipal is ahead on both scale and growth rate.

Revenue from operations grew from Rs 61.7 bn in FY24 to Rs 82.4 bn in FY25 and Rs 103.4 bn in FY26. Including other income, total income reached Rs 105.2 bn in FY26, up 26% year-on-year (YoY).

Over the FY24 to FY26 period, revenue compounded at roughly 29.4%. Consolidated revenue rose from Rs 70.3 bn in FY25 to Rs 83.7 bn in FY26, growth of just over 19%. On a network basis, gross revenue grew 16% to Rs 105.4 bn.

Both companies are growing well, but the sources of that growth differ in an important way. Manipal's top line has been lifted substantially by acquisitions, AMRI, Medica Synergie, and Sahyadri.

Meanwhile, Max has grown largely organically through brownfield expansion, adding roughly 1,500 beds during FY26 including a 160-bed expansion at Mohali and the first phase at Nanavati Max in Mumbai. Inpatient volumes rose 13% and outpatient volumes 18%.

Revenue

# Profitability

Here the comparison turns sharply in Max's favour. Manipal's revenue grew 26% in FY26. Its profit after tax fell 15%, from Rs 10.8 bn in FY25 to Rs 9.2 bn in FY26.

That divergence has clear causes. Borrowings more than doubled in a single year, largely to fund the Sahyadri acquisition, which was financed through Rs 53.1 bn of non-convertible debentures carrying a 9% coupon. Interest costs, employee costs, and depreciation all rose sharply.

The Sahyadri deal was also margin dilutive. In FY25, Sahyadri earned an 18.6% EBITDA margin against Manipal's own 26%. It contributed 5.7% of FY26 revenue while posting a loss after tax of Rs 407 m. Manipal's EBITDA margin has compressed from 27.3% in FY24 to around 25.3% in FY26.

Max moved in the opposite direction. FY26 net profit rose 34% to Rs 14.4 bn on revenue growth of 19%, meaning profit grew nearly twice as fast as the top line. On a network basis, EBITDA grew 14% to Rs 26.4 bn and PAT grew 22% to Rs 16.3 bn.

Max's network EBITDA margin held at roughly 26.8% in the March 2026 quarter, and EBITDA per bed stood at Rs 7.34 m.

One caveat worth noting is that Max's FY26 profit was helped by a favourable tax impact of Rs 1.49 bn arising from the merger of Crosslay Remedies and Jaypee Healthcare. And it has flagged clinician costs rising nearly 230 basis points YoY as it hires aggressively for future capacity.

Profitability

# Operating Efficiency

In hospitals, two metrics tell you almost everything: average revenue per occupied bed (ARPOB) and occupancy.

ARPOB measures how much revenue a hospital extracts from each bed it fills each day. It reflects case mix, pricing power and the ability to attract complex, high-value procedures. Occupancy tells you how much of the built capacity is actually being used.

Max leads decisively on ARPOB, at Rs 77,000-78,000 per occupied bed per day, the highest among listed Indian hospital chains. Manipal's ARPOB stands at about Rs 66,000, below both Max and Fortis.

This single number explains much of the valuation gap. Max earns roughly 18% more from every occupied bed than Manipal does, before considering any difference in cost structure.

On occupancy, Max ran at 75% in the March 2026 quarter, with existing mature units closer to 80%.

Manipal's position here is more nuanced. Of its 13,037 licensed beds, only around 6,227 were operational. That is a large gap between capacity built and capacity used.

It's a risk if those beds stay empty, and an opportunity if they fill, because incremental occupancy in an existing hospital flows through to profit at very high margins.

Manipal has been improving. Inpatient volumes rose from 330,000 in FY24 to 530,000 in FY26, a 26.3% compound rate, while average length of stay fell from 2.93 days to 2.78 days.

Operating Efficiency

# Debt Management

This is where the two companies diverge most starkly today.

Manipal carried gross debt of roughly Rs 111.9 bn as of 31 May 2026, having taken on Rs 53.1 bn of NCDs at a 9% coupon to fund the Sahyadri acquisition. That interest burden is a direct drag on profit, and it is the primary reason FY26 earnings fell despite strong revenue growth.

The IPO is designed to fix this. Of the Rs 80 bn fresh issue, Rs 53.8 bn is earmarked for repaying borrowings at subsidiary Manipal Hospitals. A further Rs 5.7 bn is for acquiring a minority stake in Sahyadri. Its management expects the company to be close to net debt free after the repayment.

If that happens, the interest line falls away and reported profit should recover meaningfully.

Max Healthcare operates from a considerably more comfortable position, funding its brownfield expansion largely through internal accruals.

It generated operating cash flow of Rs 16.3 bn in FY26, up from Rs 14.6 bn the previous year, and its free cash from operations has remained positive through its expansion phase.

# Financial Efficiency

To measure how effectively a company runs its business, we look at return ratios, principally return on equity (RoE) and return on capital employed (RoCE).

Neither company scores spectacularly here, which is characteristic of hospitals. Building a hospital is enormously capital-intensive, and it takes years for a new facility to reach the occupancy at which it earns well.

Max Healthcare's return on net worth stood at 13.42% in FY26, with a book value per share of Rs 110.43. Over the last three years, its return on equity has averaged around 13.7%.

Manipal's return on net worth compressed to 10.57% in FY26, down from earlier levels, reflecting the profit decline and the enlarged capital base following acquisitions.

Max leads, but both trail the sector's best. For context, Apollo Hospitals posted a return on equity of roughly 18.4%.

Max's returns have been improving as its mature hospitals fill up. Manipal's have been falling as it absorbs acquisitions and carries the associated debt. Whether Manipal's ratios recover depends almost entirely on debt repayment and occupancy gains.

Financial Efficiency

# Valuations

To know what a company is actually worth, we look at valuation ratios, principally price to earnings (PE) and price to book value (PB). A company is considered expensive if its ratios sit above its peers, and cheap if below.

Both of these stocks are expensive. One is extremely so.

At its IPO price of Rs 590, Manipal was valued at roughly Rs 776 bn, which works out to about 85 times FY26 earnings. That is a substantial premium to every listed hospital peer, including Apollo.

Max Healthcare trades at roughly 52 times forward earnings, which is demanding by any normal standard but noticeably cheaper than Manipal.

Valuations

Which Hospital Stock is Better: Manipal Health or Max Healthcare?

On revenue growth and sheer scale, Manipal leads. On profitability, operating efficiency, balance sheet strength and return ratios, Max Healthcare leads clearly.

The two companies are really running different strategies.

Manipal is a scale-and-consolidation play. It has assembled the largest bed network in India through acquisition, and it now has to make that network earn. The path is specific: repay roughly Rs 53.8 bn of debt from IPO proceeds, integrate Sahyadri, lift ARPOB from Rs 66,000 toward peer levels, and convert 13,037 licensed beds into far more than the current 6,227 operational ones.

Max is a density-and-pricing play. It runs fewer hospitals in richer catchments, earns the highest revenue per bed in the industry, funds expansion from its own cash flows, and is steadily raising the share of high-value oncology work. Its growth is slower, but it is organic, self-funded, and already profitable at the unit level.

The risks differ for both. For Manipal, they are execution and leverage. For Max, the risks are concentration in Delhi NCR, rising clinician costs, regulatory pressure on pricing through CGHS tariffs, and valuations.

Both companies are well positioned in a sector where demand is structurally rising, and organised players keep taking share from unorganised ones.

Evaluate each company's business quality, financial performance, management execution, corporate governance, and valuation as key factors before drawing any investment conclusions.

Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. Learn more about our recommendation services here...